Data / Research funding / Immunotherapy
Immunotherapy: 6,353 NIH awards ($7.8B) to 690 organizations
6,353 NIH awards ($7.8B) in the NIH spending category Immunotherapy, to 690 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 6,353 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $69,157,920 | January 20, 1997 | March 31, 2026 | VICKERS, SELWYN M | reporter.nih.gov |
| NCI Early Career Cancer Clinical Investigator Award | NIH | National Cancer Institute | 2021 to 2025 | $65,560,307 | March 10, 1997 | November 30, 2026 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $57,987,348 | March 21, 2022 | March 31, 2022 | GILBERT, PETER B. | reporter.nih.gov |
| Abramson Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $48,027,008 | January 15, 1997 | May 31, 2026 | VONDERHEIDE, ROBERT H. | reporter.nih.gov |
| Regional Oncology Research Center | NIH | National Cancer Institute | 2021 to 2025 | $40,980,320 | May 7, 1997 | May 31, 2027 | NELSON, WILLIAM GEORGE | reporter.nih.gov |
| Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $36,418,175 | September 15, 2017 | August 31, 2031 | HAMADANI, MEHDI HUSSAIN | reporter.nih.gov |
| Childhood Asthma in Urban Settings Clinical Research Network - Leadership Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $34,858,092 | April 12, 2021 | March 31, 2028 | JACKSON, DANIEL J | reporter.nih.gov |
| Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $33,014,143 | September 25, 2023 | April 30, 2027 | BERRY, JAMES DALE | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $32,609,322 | August 2, 2001 | June 30, 2027 | EBERLEIN, TIMOTHY J. | reporter.nih.gov |
| A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research | NIH | National Cancer Institute | 2021 to 2025 | $30,268,190 | March 1, 1998 | February 29, 2028 | SHAW, BRONWEN | reporter.nih.gov |
| Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $30,092,882 | August 16, 2021 | April 30, 2027 | PERSAUD, DEBORAH | reporter.nih.gov |
| BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $29,083,069 | August 16, 2021 | April 30, 2027 | MONTANER, LUIS J | reporter.nih.gov |
| Case Comprehensive Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $28,812,474 | August 1, 1997 | March 31, 2030 | SCHWARTZ, GARY K | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $28,807,695 | December 1, 1996 | March 31, 2030 | TEITELL, MICHAEL A | reporter.nih.gov |
| Delaney AIDS Research Enterprise to Cure HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $26,967,938 | August 16, 2021 | April 30, 2027 | DEEKS, STEVEN GRANT | reporter.nih.gov |
| B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $26,314,793 | June 1, 2022 | May 31, 2027 | HUNTER, ERIC | reporter.nih.gov |
| ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $25,334,968 | August 16, 2021 | June 12, 2026 | PAIARDINI, MIRKO | reporter.nih.gov |
| I4C 2.0: Immunotherapy for Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,329,181 | August 16, 2021 | April 30, 2027 | BAROUCH, DAN H. | reporter.nih.gov |
| SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,986,953 | September 2, 2022 | June 30, 2027 | WILLIAMS, WILTON B | reporter.nih.gov |
| UCCC P30 Supplement: Human Endogenous Retrovirus-H as a Target for Early-Onset Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $21,851,455 | September 1, 2025 | August 31, 2026 | SCHULICK, RICHARD D | reporter.nih.gov |
| Kansas IDeA Network of Biomedical Research Excellence 5 | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $21,278,824 | September 18, 2001 | April 30, 2029 | WRIGHT, DOUGLAS E | reporter.nih.gov |
| Reversing Immune Dysfunction for HIV-1 Eradication | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $20,001,273 | August 16, 2021 | October 31, 2026 | CHANDA, SUMIT K | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $19,528,719 | June 1, 1997 | June 30, 2028 | STEIDL, ULRICH | reporter.nih.gov |
| Pediatric Brain Tumor Consortium A multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors | NIH | National Cancer Institute | 2021 to 2025 | $18,653,803 | April 1, 1999 | March 31, 2026 | ONAR-THOMAS, ARZU | reporter.nih.gov |
| Biology of the Hormonal Regulation of Cancer and Immuno Oncology Outcomes Research Proposal. | NIH | National Cancer Institute | 2021 to 2025 | $15,746,743 | August 1, 1997 | June 30, 2027 | COUSSENS, LISA M | reporter.nih.gov |
| Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,471,597 | September 14, 2021 | June 30, 2028 | MADSEN, JOREN C | reporter.nih.gov |
| A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $15,144,108 | September 15, 2021 | August 31, 2027 | CLARDY, STACEY LYNN | reporter.nih.gov |
| Consolidated Basic Cancer Research Program | NIH | National Cancer Institute | 2021 to 2025 | $14,936,465 | April 1, 1997 | February 28, 2026 | ALTIERI, DARIO C | reporter.nih.gov |
| Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,843,451 | August 20, 2021 | May 31, 2028 | NAJI, ALI | reporter.nih.gov |
| Center for Cancer Immunology and Immunotherapy (CCII) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $14,096,415 | February 1, 2020 | May 31, 2030 | YAN, JUN | reporter.nih.gov |
| OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2023 | $13,778,020 | September 30, 2021 | July 31, 2025 | STEVENS, MISTY WARD | reporter.nih.gov |
| Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $13,418,019 | June 15, 2021 | May 31, 2027 | ALONSO, ESTELLA M. | reporter.nih.gov |
| Collaborative Pediatric Critical Care Research Network | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $12,717,344 | August 13, 2021 | July 31, 2026 | WATT, KEVIN M | reporter.nih.gov |
| Personalized Modeling of CAR-T Cell Immunotherapy Using iPSC-Derived Effectors and Patient- Derived Tumor Organoids | NIH | National Cancer Institute | 2023 to 2025 | $12,675,268 | March 1, 1997 | August 31, 2026 | LIBUTTI, STEVEN K. | reporter.nih.gov |
| Tissue and organ specific human B cell immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $12,146,380 | April 1, 2019 | March 31, 2025 | LUND, FRANCES E. | reporter.nih.gov |
| Human anti-viral immune responses in tissues and circulation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,930,741 | January 1, 2017 | February 28, 2027 | FARBER, DONNA L. | reporter.nih.gov |
| Targeting the B Cell Response to Treat Antibody-Mediated Rejection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,789,092 | August 20, 2021 | May 31, 2028 | KNECHTLE, STUART JOHNSTON | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| A Global Map of Interactions Among Human Cell Surface Proteins and Secreted Ligands | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $11,281,013 | September 30, 2022 | August 31, 2027 | ZINN, KAI G | reporter.nih.gov |
| Utility of Biomarkers of Rejection and Kidney Injury in Tailoring Liver Transplant Immunosuppression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,920,671 | September 6, 2021 | June 30, 2028 | BOIKE, JUSTIN | reporter.nih.gov |
| Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics) | NIH | National Cancer Institute | 2022 to 2025 | $10,596,037 | September 22, 2022 | August 31, 2027 | HEATH, JAMES R. | reporter.nih.gov |
| SPORE in Brain Cancer | NIH | National Cancer Institute | 2021 to 2025 | $10,413,880 | September 1, 2008 | August 31, 2029 | LANG, FREDERICK F | reporter.nih.gov |
| Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | NIH | National Institute on Aging | 2022 to 2025 | $10,320,460 | February 15, 2022 | January 31, 2027 | AGADJANYAN, MICHAEL G | reporter.nih.gov |
| Colorado Head and Neck Cancer SPORE | NIH | National Cancer Institute | 2021 to 2025 | $10,073,085 | September 1, 2021 | August 31, 2026 | JIMENO, ANTONIO | reporter.nih.gov |
| Yale SPORE in Skin Cancer | NIH | National Cancer Institute | 2021 to 2025 | $9,801,266 | June 1, 2006 | August 31, 2028 | BOSENBERG, MARCUS W | reporter.nih.gov |
| Center for Modeling Complex Interactons | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $9,684,540 | March 15, 2015 | June 30, 2025 | WICHMAN, HOLLY A | reporter.nih.gov |
| Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $9,412,704 | September 22, 2020 | June 30, 2026 | BURTNESS, BARBARA | reporter.nih.gov |
| Immune Cell Interactions in Atherosclerosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $9,386,571 | August 1, 2017 | May 31, 2027 | HEDRICK, CATHERINE C | reporter.nih.gov |
| Translational Research in Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $9,097,808 | September 19, 2014 | July 31, 2026 | ZHANG, XIANG | reporter.nih.gov |
| Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis Pathobiology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $8,479,606 | May 1, 2021 | April 30, 2027 | EFRON, PHILIP A | reporter.nih.gov |
| Immunotherapy for Ocular Surface Diseases | NIH | National Eye Institute | 2021 to 2025 | $8,312,140 | February 1, 2021 | December 31, 2026 | JAIN, SANDEEP | reporter.nih.gov |
| Consortia for Innovative AIDS Research in Nonhuman Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $8,268,168 | May 1, 2016 | April 30, 2022 | BAROUCH, DAN H. | reporter.nih.gov |
| Manufacturing of Drug Product, Dual Aβ/tau Vaccine for Clinical Trials | NIH | National Institute on Aging | 2021 to 2023 | $8,244,109 | February 1, 2019 | January 31, 2025 | AGADJANYAN, MICHAEL G | reporter.nih.gov |
| Alzheimer's Prevention Initiative ADAD Colombia Trial | NIH | National Institute on Aging | 2021 to 2022 | $8,118,116 | April 1, 2017 | September 30, 2024 | REIMAN, ERIC MICHAEL | reporter.nih.gov |
| Ad26 Based Therapeutic Vaccines for HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,518,476 | May 12, 2020 | April 30, 2027 | BAROUCH, DAN H. | reporter.nih.gov |
| SPORE in Breast Cancer | NIH | National Cancer Institute | 2021 to 2024 | $7,513,457 | August 1, 2024 | July 31, 2025 | PIETENPOL, JENNIFER A | reporter.nih.gov |
| Strategies to Optimize Pig-to-Primate Kidney Xenograft Survival | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,360,026 | July 1, 2016 | June 30, 2030 | ADAMS, ANDREW B | reporter.nih.gov |
| Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting | NIH | National Cancer Institute | 2023 to 2025 | $7,201,689 | June 1, 2021 | May 31, 2027 | AMBROSONE, CHRISTINE B. | reporter.nih.gov |
| Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,813,637 | April 14, 2020 | July 31, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| Small-molecule activators of STING-signaling as novel adjuvants for flavivirus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,461,817 | September 30, 2019 | September 29, 2024 | NELSON, JAY | reporter.nih.gov |
| Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,461,018 | August 9, 2022 | May 31, 2027 | HERSCHHORN, ALON | reporter.nih.gov |
| DUAL AFFINITY RE-TARGETING (DART) MOLECULES FOR HIV-1 SUPPRESSION | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $6,287,950 | September 15, 2015 | July 14, 2023 | NORDSTROM, JEFFREY | reporter.nih.gov |
| Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2023 | $6,265,868 | February 1, 2021 | November 30, 2026 | POTTER, HUNTINGTON | reporter.nih.gov |
| Interferon Signaling in the T1D Islet Microenvironment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $6,240,105 | September 15, 2020 | August 31, 2029 | MIRMIRA, RAGHAVENDRA G | reporter.nih.gov |
| A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,096,179 | September 5, 2023 | June 30, 2028 | SHAPIRO, ROGER L | reporter.nih.gov |
| High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials | NIH | National Cancer Institute | 2023 to 2025 | $5,867,691 | September 30, 2017 | June 30, 2028 | GNJATIC, SACHA | reporter.nih.gov |
| Sonogenetic Remote Control of Cellular Function | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $5,862,500 | September 30, 2021 | July 31, 2027 | SHAPIRO, MIKHAIL | reporter.nih.gov |
| Novel Biologic Therapies for GVHD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $5,851,412 | February 1, 2010 | June 30, 2026 | KEAN, LESLIE S | reporter.nih.gov |
| Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,841,904 | September 30, 2019 | April 30, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD) | NIH | National Institute on Aging | 2021 to 2023 | $5,749,685 | September 1, 2021 | August 31, 2024 | YOLES, ETI | reporter.nih.gov |
| Cancer Immune Monitoring and Analysis Center | NIH | National Cancer Institute | 2023 to 2025 | $5,746,876 | September 30, 2017 | June 30, 2028 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Decoding And Targeting The LKB1-AMPK Signaling Pathway In Cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,725,440 | August 1, 2017 | July 31, 2031 | SHAW, REUBEN | reporter.nih.gov |
| MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC | NIH | National Cancer Institute | 2023 to 2025 | $5,677,452 | September 30, 2017 | June 30, 2028 | HAYMAKER, CARA L | reporter.nih.gov |
| Small-molecule inducers of the cGAS/STING pathway as novel adjuvants for flu vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,636,289 | September 30, 2019 | September 29, 2024 | ADOLFO, GARCIA-SASTRE | reporter.nih.gov |
| Overcoming resistance to anti-PD1 immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $5,629,363 | December 7, 2016 | August 31, 2030 | GAJEWSKI, THOMAS F | reporter.nih.gov |
| OSU as a Network Lead Academic Participating Site for the NCI NCTN | NIH | National Cancer Institute | 2021 to 2025 | $5,610,699 | March 28, 2019 | February 28, 2026 | VERSCHRAEGEN, CLAIRE F. | reporter.nih.gov |
| Stanford Cancer Immune Monitoring and Analysis Center (CIMAC) | NIH | National Cancer Institute | 2023 to 2025 | $5,504,598 | September 30, 2017 | June 30, 2028 | MAECKER, HOLDEN T. | reporter.nih.gov |
| Small-molecule adjuvants testing pipeline (Influenza) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,486,225 | September 30, 2019 | September 29, 2024 | LEVY, OFER | reporter.nih.gov |
| Finding Sleeping Beauty: T Cell Biosensors for Dormant Cancer Detection | NIH | National Cancer Institute | 2022 to 2025 | $5,481,630 | September 20, 2022 | August 31, 2027 | KWONG, GABRIEL A | reporter.nih.gov |
| Molecular mechanisms of antibody-mediated immunotherapies | NIH | National Cancer Institute | 2021 to 2025 | $5,461,259 | April 1, 2016 | August 31, 2029 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,339,746 | February 20, 2018 | January 31, 2026 | SHAPIRO, ROGER L | reporter.nih.gov |
| FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants. | NIH | National Institute on Aging | 2025 | $5,308,961 | August 1, 2025 | July 31, 2030 | AGADJANYAN, MICHAEL G | reporter.nih.gov |
| The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network | NIH | National Cancer Institute | 2021 to 2025 | $5,286,341 | March 28, 2014 | February 28, 2027 | CARSON, WILLIAM E. | reporter.nih.gov |
| Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | NIH | National Institute on Drug Abuse | 2021 to 2022 | $5,281,643 | May 1, 2020 | February 29, 2024 | STEVENS, MISTY WARD | reporter.nih.gov |
| Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery | NIH | National Cancer Institute | 2021 to 2025 | $5,246,301 | August 1, 2015 | July 31, 2028 | MEYERSON, MATTHEW L. | reporter.nih.gov |
| Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies. | NIH | National Cancer Institute | 2021 to 2025 | $5,214,422 | August 14, 2020 | July 31, 2027 | SCHEINBERG, DAVID A | reporter.nih.gov |
| Pre-cancer atlas of skin cancer | NIH | National Cancer Institute | 2024 to 2025 | $5,182,743 | September 1, 2024 | August 31, 2029 | SHAIN, ALAN HUNTER | reporter.nih.gov |
| Cellular Decision Making | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $5,164,037 | June 1, 2016 | May 31, 2026 | WEINER, ORION D | reporter.nih.gov |
| Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers | NIH | National Cancer Institute | 2021 to 2025 | $5,154,412 | September 1, 2019 | August 31, 2026 | ROBERTS, THOMAS M | reporter.nih.gov |
| Towards targeting the lymphoma microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $5,082,235 | September 1, 2020 | August 31, 2027 | WENDEL, HANS-GUIDO | reporter.nih.gov |
| Mucus-degrading intestinal bacteria and toxicities of hematopoietic cell transplantation | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $5,032,505 | September 21, 2024 | July 31, 2029 | JENQ, ROBERT | reporter.nih.gov |
| Integrating targeted therapy and immunotherapy to break through cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,025,838 | September 1, 2016 | August 31, 2030 | ZHAO, JEAN | reporter.nih.gov |
| Reversing Immune Dysfunction for HIV-1 Eradication | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,001,807 | August 16, 2021 | October 31, 2021 | CHANDA, SUMIT K | reporter.nih.gov |
| Reprogramming the Tumor-Immune Interface in Oral Cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $4,940,407 | September 8, 2020 | June 30, 2028 | SUNWOO, JOHN B | reporter.nih.gov |
| Integrating systems immunology with immunometabolism and cancer immunity | NIH | National Cancer Institute | 2021 to 2025 | $4,934,381 | August 1, 2021 | July 31, 2028 | CHI, HONGBO | reporter.nih.gov |
| Evolving Novel AAV Vectors for Gene Therapy to Cure HIV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,872,750 | June 7, 2022 | May 31, 2027 | SACHA, JONAH B. | reporter.nih.gov |
| Structure based design of trimer interface epitope focused universal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,864,362 | March 12, 2020 | February 28, 2025 | CROWE, JAMES E | reporter.nih.gov |
| Novel Stem Cell Immunotherapy for MDR-Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,800,190 | June 4, 2021 | May 31, 2026 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| Determine the molecular and metabolic mechanisms by which A-FABP links dysregulated lipid metabolism-induced obesity/breast cancer risk | NIH | National Cancer Institute | 2022 to 2025 | $4,769,593 | August 12, 2022 | July 31, 2027 | LI, BING | reporter.nih.gov |
| Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies | NIH | National Cancer Institute | 2022 to 2025 | $4,722,849 | June 16, 2022 | May 31, 2027 | PAULOVICH, AMANDA G | reporter.nih.gov |
| Activation of Macrophages in Human Autoimmune Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,710,162 | March 1, 2000 | July 31, 2029 | IVASHKIV, LIONEL B | reporter.nih.gov |
| Immunologic control of HIV-1 through combination bNAbs and biologics. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $4,702,057 | July 5, 2019 | December 31, 2025 | CASKEY, MARINA | reporter.nih.gov |
| Development of Innovative Resources to Advance MDS Research | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $4,661,966 | September 15, 2023 | July 31, 2028 | BLEAKLEY, MARIE | reporter.nih.gov |
| Unlocking evolutionarily latent immune functions for treating disease | NIH | National Cancer Institute | 2021 to 2024 | $4,638,420 | September 1, 2020 | August 31, 2025 | BASS, BRENDA L. | reporter.nih.gov |
| Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primates | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,613,595 | June 3, 2022 | May 31, 2027 | KAWAI, TATSUO | reporter.nih.gov |
| Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation | NIH | National Cancer Institute | 2021 to 2025 | $4,608,771 | April 1, 2017 | July 31, 2031 | COFFEY, ROBERT J. | reporter.nih.gov |
| A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform | NIH | National Center for Advancing Translational Sciences | 2021 to 2024 | $4,598,428 | July 1, 2021 | April 30, 2026 | HINGTGEN, SHAWN | reporter.nih.gov |
| Next Generation Cancer Immunotherapies to Defeat Melanoma | NIH | National Cancer Institute | 2021 to 2025 | $4,577,719 | September 9, 2015 | August 31, 2029 | RIBAS, ANTONI | reporter.nih.gov |
| THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE | NIH | National Cancer Institute | 2021 to 2025 | $4,550,196 | May 5, 2021 | April 30, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $4,541,273 | September 17, 2019 | August 31, 2026 | TING, JENNY P | reporter.nih.gov |
| Regulatory T cells and the tumor microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $4,516,979 | August 1, 2021 | July 31, 2028 | VIGNALI, DARIO AA | reporter.nih.gov |
| Impact of tuberculosis on the development and function of the immune system in SIV-infected infants | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $4,476,086 | April 1, 2019 | March 31, 2025 | WANG, XIAOLEI | reporter.nih.gov |
| Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,466,979 | May 1, 2018 | April 30, 2025 | MADSEN, JOREN C | reporter.nih.gov |
| Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,417,924 | June 3, 2022 | May 31, 2027 | GOLDSTEIN, HARRIS | reporter.nih.gov |
| Pediatric Early Phase Clinical Trials Network (PEP-CTN) Transfer Application | NIH | National Cancer Institute | 2025 | $4,394,441 | August 1, 2025 | July 31, 2029 | FOX, ELIZABETH | reporter.nih.gov |
| Signal transduction and gene induction in lymphocytes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,374,000 | August 1, 1991 | August 31, 2028 | HOGAN, PATRICK | reporter.nih.gov |
| Neonatal porcine islet xenografts for the treatment of type 1 diabetes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,363,576 | September 1, 2010 | June 30, 2025 | KIRK, ALLAN D. | reporter.nih.gov |
| Mechanism of Epigenetic Inheritance | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,320,227 | September 1, 2016 | July 31, 2026 | ZHANG, ZHIGUO | reporter.nih.gov |
| Comprehensive Characterization of the T-cell Response to KSHV to Enable Specific Immune Therapy | NIH | National Cancer Institute | 2025 | $4,234,248 | September 19, 2025 | August 31, 2029 | WARREN, EDUS HOUSTON | reporter.nih.gov |
| Progressive Multifocal Leukoenephalopathy: Endemic Viruses and Lethal Brain Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $4,225,016 | May 1, 2020 | April 30, 2028 | ATWOOD, WALTER J | reporter.nih.gov |
| The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,208,331 | June 1, 2020 | July 31, 2030 | SESHADRI, CHETAN | reporter.nih.gov |
| Antibody-based therapy for fentanyl-related opioid use disorder | NIH | National Institute on Drug Abuse | 2023 | $4,202,550 | September 30, 2023 | August 31, 2025 | DESAI, RAJEEV INDRAJIT | reporter.nih.gov |
| CD11b: A Novel Alternate Receptor for CD154 during Alloimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,188,152 | March 17, 2020 | June 30, 2029 | FORD, MANDY L | reporter.nih.gov |
| Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry | NIH | National Cancer Institute | 2021 to 2024 | $4,181,635 | June 1, 2020 | May 31, 2025 | AMBROSONE, CHRISTINE B. | reporter.nih.gov |
| Metabolic reprogramming of the tumor microenvironment and therapy resistance | NIH | National Cancer Institute | 2021 to 2025 | $4,171,362 | August 17, 2021 | July 31, 2028 | LENGYEL, ERNST | reporter.nih.gov |
| Insights from Asian Populations into Disparities in Breast Cancer Prognosis and Outcomes | NIH | National Cancer Institute | 2021 to 2024 | $4,137,490 | June 8, 2020 | May 31, 2026 | GOMEZ, SCARLETT L | reporter.nih.gov |
| The Impact of a Changing Health Care Delivery System on the Quality of Oncology Care | NIH | National Cancer Institute | 2021 to 2025 | $4,126,391 | December 15, 2020 | November 30, 2026 | KEATING, NANCY L | reporter.nih.gov |
| Translating Pediatric Cancer Proteogenomic Data into Biological and Clinical Insights | NIH | National Cancer Institute | 2022 to 2025 | $4,071,173 | June 1, 2022 | May 31, 2027 | ZHANG, BING | reporter.nih.gov |
| Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,067,768 | May 1, 2021 | April 30, 2027 | BALKO, JUSTIN M | reporter.nih.gov |
| Exploring Siglec-glycan ligand interactions using chemoenzymatic approaches | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,052,733 | June 4, 2021 | May 31, 2026 | WU, PENG | reporter.nih.gov |
| A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,049,312 | September 1, 2019 | January 31, 2026 | HOWELL, DAVID W. | reporter.nih.gov |
| Chemoenzymatic glycan editing for deciphering biological functions of glycans | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,015,088 | February 1, 2021 | January 31, 2026 | WU, PENG | reporter.nih.gov |
| Immune checkpoint inhibitors and accelerated coronary atherosclerosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,014,114 | May 1, 2022 | April 30, 2027 | NEILAN, TOMAS G | reporter.nih.gov |
| Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,009,506 | April 15, 2019 | June 30, 2027 | FRIEDMAN, HARVEY MICHAEL | reporter.nih.gov |
| HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,008,532 | April 8, 2021 | March 31, 2026 | TSIBRIS, ATHE M. | reporter.nih.gov |
| Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma | NIH | National Cancer Institute | 2022 to 2023 | $4,000,000 | March 16, 2018 | March 31, 2024 | GARYANTES, TINA | reporter.nih.gov |
| NextGen - CRI | NIH | National Cancer Institute | 2022 to 2025 | $3,968,330 | June 1, 2025 | May 31, 2026 | BOLLARD, CATHERINE M. | reporter.nih.gov |
| Preclinical development of breakthrough immunotherapy for brain tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,949,492 | December 15, 2017 | November 30, 2025 | OKADA, HIDEHO | reporter.nih.gov |
| High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,939,372 | April 15, 2021 | March 31, 2027 | LI, HONGMIN | reporter.nih.gov |
| Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,932,444 | September 30, 2017 | August 31, 2032 | MARIS, JOHN M | reporter.nih.gov |
| Fibroblast Heterogeneity in Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,931,956 | August 10, 2021 | July 31, 2026 | TUVESON, DAVID A | reporter.nih.gov |
| Harnessing engineered T regulatory cells to promote beta cell health in T1D | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,920,533 | April 8, 2022 | January 31, 2026 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Proteogenomic Predictors of Recurrence in Non-small Cell Lung Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,920,220 | June 13, 2022 | May 31, 2027 | GOVINDAN, RAMASWAMY | reporter.nih.gov |
| Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability | NIH | National Cancer Institute | 2021 to 2024 | $3,915,629 | August 1, 2018 | July 31, 2025 | IACOBUZIO-DONAHUE, CHRISTINE A | reporter.nih.gov |
| A physical sciences approach to investigate the role of exosomes in metastatic progression | NIH | National Cancer Institute | 2021 to 2025 | $3,903,970 | September 16, 2021 | August 31, 2026 | RADHAKRISHNAN, RAVI | reporter.nih.gov |
| Induction of autophagy to enhance CAR-T cells in HIV cure approaches | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,855,196 | June 25, 2022 | May 31, 2027 | ZHEN, ANJIE | reporter.nih.gov |
| T cells in the aging brain | NIH | National Institute on Aging | 2021 to 2025 | $3,850,998 | June 15, 2021 | March 31, 2027 | BRUNET, ANNE | reporter.nih.gov |
| Immunomodulation Approaches to Improve Safety And Efficacy of Gene Therapy Treatment in Friedreich’s Ataxia | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,844,243 | May 1, 2021 | August 31, 2026 | CORTI, MANUELA | reporter.nih.gov |
| Mechanisms of protection against shigellosis in children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,843,317 | June 9, 2022 | May 31, 2027 | PASETTI, MARCELA F | reporter.nih.gov |
| Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,828,356 | September 1, 2021 | August 31, 2026 | GLENN, JEFFREY S | reporter.nih.gov |
| Immune Dysfunction in HIV+ Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,823,539 | April 15, 2020 | January 31, 2027 | PAHWA, SAVITA | reporter.nih.gov |
| Harnessing adaptive NK cell transfer to deplete viral reservoirs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,812,634 | April 16, 2021 | March 31, 2027 | EVANS, DAVID T | reporter.nih.gov |
| Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance | NIH | National Cancer Institute | 2021 to 2024 | $3,811,506 | May 1, 2020 | August 31, 2025 | CHAN, TIMOTHY AN-THY | reporter.nih.gov |
| Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,805,993 | June 1, 2021 | May 31, 2027 | LIAO, ZHONGXING | reporter.nih.gov |
| Natural killer cell engineering to target the HIV reservoir | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,790,684 | April 1, 2021 | March 31, 2026 | ZACK, JEROME A. | reporter.nih.gov |
| Activated NK CAR Cells to Cure HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,780,061 | April 2, 2021 | March 31, 2027 | SKINNER, PAMELA J | reporter.nih.gov |
| Image-based models of tumor-immune dynamics in glioblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,775,245 | March 1, 2021 | February 28, 2027 | HU, LELAND | reporter.nih.gov |
| Human natural killer cells: Advancing biology and clinical applications | NIH | National Cancer Institute | 2021 to 2025 | $3,769,374 | July 21, 2017 | June 30, 2032 | CALIGIURI, MICHAEL A | reporter.nih.gov |
| Dissecting CCL5 contribution to antigen specific T cell responses in head and neck cancers | NIH | National Institute of Dental & Craniofacial Research | 2025 | $3,742,682 | August 21, 2025 | August 20, 2029 | UPPALURI, RAVINDRA | reporter.nih.gov |
| Multi-OMICS identification and validation of mechanisms triggered by Immune interventions aimed at reducing the size of the replication competent Reservoir | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,741,426 | July 3, 2023 | April 30, 2028 | SEKALY, RAFICK PIERRE | reporter.nih.gov |
| Single-Cell Analysis of the HIV/SIV Reservoir | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,716,718 | June 10, 2020 | May 31, 2026 | BAROUCH, DAN H. | reporter.nih.gov |
| "Corral and Kill" strategy for HIV eradication using MSC in an SIV model | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,712,736 | March 23, 2020 | February 28, 2030 | DANDEKAR, SATYA | reporter.nih.gov |
| Exploiting antibody catalysis for treating Cryptococcosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,699,200 | May 25, 2021 | April 30, 2027 | CASADEVALL, ARTURO | reporter.nih.gov |
| Combined cytokine therapy for sustained HIV remission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,695,050 | March 17, 2020 | February 28, 2026 | VELU, VIJAYAKUMAR | reporter.nih.gov |
| YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAM | NIH | National Cancer Institute | 2021 to 2025 | $3,691,379 | March 1, 2018 | August 31, 2028 | KLUGER, HARRIET M. | reporter.nih.gov |
| Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $3,687,540 | September 7, 2017 | June 30, 2032 | DIPERSIO, JOHN F. | reporter.nih.gov |
| Enhancing immune regulation in gene therapy for hemophilia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,664,714 | July 1, 2016 | June 30, 2029 | HERZOG, ROLAND W. | reporter.nih.gov |
| Studying factors controlling cancer progression and immune recognition in mouse models | NIH | National Cancer Institute | 2022 to 2025 | $3,664,660 | September 20, 2022 | August 31, 2029 | JACKS, TYLER E. | reporter.nih.gov |
| Structure, Function and Mechanistic Analysis of LAG3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,664,179 | January 8, 2019 | December 31, 2028 | VIGNALI, DARIO AA | reporter.nih.gov |
| Michigan Center for Translational Cancer Proteogenomics | NIH | National Cancer Institute | 2022 to 2025 | $3,656,494 | June 6, 2022 | May 31, 2027 | NESVIZHSKII, ALEXEY I | reporter.nih.gov |
| Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,648,726 | August 15, 2015 | May 31, 2026 | SARANTOPOULOS, STEFANIE | reporter.nih.gov |
| Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,631,144 | March 4, 2019 | February 28, 2025 | SCANGA, CHARLES A. | reporter.nih.gov |
| NGTC - UCL | NIH | National Cancer Institute | 2022 to 2024 | $3,627,871 | June 1, 2024 | May 31, 2025 | PULE, MARTIN | reporter.nih.gov |
| Understanding Immune Evasion by HIV-1 Repliclones | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,617,103 | June 10, 2021 | May 31, 2027 | HALVAS, ELIAS K. | reporter.nih.gov |
| ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial | NIH | National Eye Institute | 2021 to 2022 | $3,613,158 | September 30, 2018 | August 31, 2025 | HOLBROOK, JANET T. | reporter.nih.gov |
| Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,610,454 | August 5, 2021 | July 31, 2025 | RENGARAJAN, JYOTHI | reporter.nih.gov |
| Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV | NIH | National Institute of Mental Health | 2022 to 2025 | $3,610,311 | August 5, 2022 | May 31, 2027 | SKINNER, PAMELA J | reporter.nih.gov |
| Optimizing AAV delivery of bNAbs for HIV prevention | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,607,044 | November 24, 2021 | October 31, 2026 | GARDNER, MATTHEW RYAN | reporter.nih.gov |
| HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,601,018 | April 9, 2021 | March 31, 2027 | HSU, KATHARINE C | reporter.nih.gov |
| Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism | NIH | National Cancer Institute | 2021 to 2025 | $3,588,137 | September 22, 2021 | August 31, 2027 | DENKO, NICHOLAS C. | reporter.nih.gov |
| Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal | NIH | National Cancer Institute | 2021 to 2025 | $3,585,446 | July 1, 2010 | June 30, 2027 | NAKAGAWA, MAYUMI | reporter.nih.gov |
| Regulators of immune complex mediated neutrophil antigen presentation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,580,976 | September 30, 1999 | February 28, 2027 | MAYADAS, TANYA N | reporter.nih.gov |
| Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,575,135 | December 24, 2018 | November 30, 2024 | BRANCO, LUIS MANUEL | reporter.nih.gov |
| Individualized HIV Curative Combination Strategy against Persistent HIV on ART | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,568,644 | July 7, 2025 | May 31, 2030 | MONTANER, LUIS J | reporter.nih.gov |
| NCI Pediatric In Vivo Testing Program: Neuroblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,549,742 | July 1, 2021 | June 30, 2027 | MOSSE, YAEL P | reporter.nih.gov |
| Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $3,549,010 | July 8, 2021 | February 28, 2027 | SHARMA, SONIA | reporter.nih.gov |
| Probing cytosolic nucleic acid sensing pathways in cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,548,978 | January 1, 2021 | December 31, 2026 | LAUGHNEY, ASHLEY MARIE | reporter.nih.gov |
| KIR and MHC Class I Immunogenetics in SIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,547,833 | December 18, 2023 | October 31, 2028 | EVANS, DAVID T | reporter.nih.gov |
| Identification of Lethal Melanomas at the Time of Diagnosis | NIH | National Cancer Institute | 2021 to 2024 | $3,546,906 | April 1, 2020 | March 31, 2026 | THOMAS, NANCY E. | reporter.nih.gov |
| Novel mechanisms regulating immunity to respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,546,288 | August 2, 2023 | July 31, 2027 | PAUST, SILKE | reporter.nih.gov |
| Preventing GVHD by inhibition of alloantigen presentation in the gut | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,543,040 | July 1, 2019 | June 30, 2027 | HILL, GEOFFREY ROGER | reporter.nih.gov |
| Ocular Immune Regulation by Mesenchymal Stem Cells | NIH | National Eye Institute | 2021 to 2025 | $3,542,949 | April 1, 2015 | September 14, 2028 | CHAUHAN, SUNIL K | reporter.nih.gov |
| Synthetic circuit technologies for precision control and signal processing in mammalian cells | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $3,539,495 | May 1, 2020 | April 30, 2028 | KHALIL, AHMAD SAMIR | reporter.nih.gov |
| Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,521,872 | August 1, 2024 | July 31, 2029 | BARBIER, MARIETTE | reporter.nih.gov |
| Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,515,485 | September 19, 2022 | July 31, 2027 | SAGAR, MANISH | reporter.nih.gov |
| De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,504,899 | August 2, 2021 | July 31, 2026 | BAKER, DAVID | reporter.nih.gov |
| Turning off HIV White Noise: Switching from Long-Lived to Short-Lived Reservoir | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,500,544 | March 22, 2023 | February 29, 2028 | MARTINELLI, ELENA | reporter.nih.gov |
| Variation in tumor-associated immune profiles and colorectal cancer outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,497,316 | September 15, 2021 | August 31, 2027 | SCHMIT, STEPHANIE L. | reporter.nih.gov |
| Leveraging fructose transport to create a privileged substrate to selectively fuel T cells | NIH | National Cancer Institute | 2021 to 2025 | $3,492,795 | December 11, 2020 | November 30, 2025 | KESHARI, KAYVAN R | reporter.nih.gov |
| Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells | NIH | National Cancer Institute | 2021 to 2025 | $3,469,484 | January 7, 2021 | December 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| The regulatory role of natural progesterone in barrier immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,469,332 | September 21, 2022 | July 31, 2027 | HLADIK, FLORIAN | reporter.nih.gov |
| Deciphering Early Stages of Polyomavirus CNS Pathogenesis and Immunity | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,466,474 | May 1, 2022 | April 30, 2030 | LUKACHER, ARON ELIOT | reporter.nih.gov |
| ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center | NIH | National Cancer Institute | 2021 to 2025 | $3,465,294 | January 2, 2025 | February 28, 2026 | LEAL, TICIANA | reporter.nih.gov |
| Evolution of gliomas during treatment and resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,464,231 | April 1, 2015 | June 30, 2026 | BEROUKHIM, RAMEEN | reporter.nih.gov |
| A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab | NIH | National Cancer Institute | 2022 to 2025 | $3,457,194 | August 14, 2025 | July 31, 2028 | KAADIGE, MOHAN RAO | reporter.nih.gov |
| New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,453,304 | December 10, 2020 | November 30, 2025 | NEEL, BENJAMIN G. | reporter.nih.gov |
| Role of Trem1 in ultraviolet radiation-induced immune suppression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,453,128 | June 18, 2021 | May 31, 2027 | YUSUF, NABIHA | reporter.nih.gov |
| Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,448,227 | December 10, 2020 | November 30, 2025 | NEEL, BENJAMIN G. | reporter.nih.gov |
| Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity | NIH | National Cancer Institute | 2021 to 2025 | $3,445,316 | January 1, 2021 | December 31, 2026 | EVANS, SHARON S | reporter.nih.gov |
| Biomaterials-directed regenerative immunotherapies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $3,438,750 | September 25, 2019 | August 31, 2025 | ELISSEEFF, JENNIFER H | reporter.nih.gov |
| TLE transcription cofactors in anti-viral and anti-tumor immunity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,436,588 | July 18, 2025 | June 30, 2029 | XUE, HAI-HUI | reporter.nih.gov |
| Reducing Latent Viral Reservoirs in Infant Macaques | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $3,436,436 | August 1, 2014 | June 30, 2025 | HAIGWOOD, NANCY L | reporter.nih.gov |
| Investigating Macrophage Molecular and Functional Diversity in Tumor Immunity | NIH | National Cancer Institute | 2021 to 2025 | $3,431,899 | February 1, 2021 | January 31, 2026 | MERAD, MIRIAM | reporter.nih.gov |
| Exploring DNA damage response pathways as targets for cancer therapy | NIH | National Cancer Institute | 2022 to 2025 | $3,431,390 | September 1, 2022 | August 31, 2029 | CHEN, JUNJIE | reporter.nih.gov |
| Metformin for chemoprevention of lung cancer in obese subjects at high risk | NIH | National Cancer Institute | 2021 to 2025 | $3,423,650 | August 1, 2021 | July 31, 2027 | YENDAMURI, SAIKRISHNA | reporter.nih.gov |
| Population Modeling of Bladder Cancer Detection and Control | NIH | National Cancer Institute | 2021 to 2025 | $3,415,778 | September 13, 2021 | August 31, 2026 | TRIKALINOS, THOMAS | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| CAR-T cell treatment of CNS Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,403,175 | June 13, 2022 | May 31, 2027 | WU, GREGORY | reporter.nih.gov |
| Stratifying Patient Immune Endotypes in Sepsis (SPIES Study) | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $3,390,895 | September 5, 2020 | June 30, 2026 | MAILE, ROBERT | reporter.nih.gov |
| Tumor Plasticity | NIH | National Cancer Institute | 2021 to 2023 | $3,374,400 | September 1, 2017 | August 31, 2024 | ALTIERI, DARIO C | reporter.nih.gov |
| Microphysiological systems for modeling autoimmunity in type 1 diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,372,768 | August 2, 2019 | July 31, 2025 | STANGER, BEN Z | reporter.nih.gov |
| NFAT, bZIP proteins, and transcriptional programs in lymphocytes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,369,412 | August 1, 2014 | February 28, 2025 | HOGAN, PATRICK | reporter.nih.gov |
| UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center | NIH | National Cancer Institute | 2021 to 2025 | $3,358,438 | March 13, 2019 | February 28, 2026 | MERKER, JASON DEREK | reporter.nih.gov |
| Neuroprotective Immunity and HIV Dementia | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,351,926 | April 15, 1995 | February 29, 2028 | GENDELMAN, HOWARD E | reporter.nih.gov |
| AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS | NIH | National Cancer Institute | 2021 to 2025 | $3,349,717 | July 1, 2021 | June 30, 2027 | GUCCIONE, ERNESTO | reporter.nih.gov |
| Innate Immune Activation in Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,341,812 | September 24, 2009 | February 28, 2025 | GOLENBOCK, DOUGLAS T | reporter.nih.gov |
| Immunologic correlates of functional cure of HBV with immune checkpoint blockade | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,338,136 | May 22, 2020 | April 30, 2026 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| Development of an mRNA-Based Therapeutic HIV/AIDS Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,336,113 | March 5, 2020 | February 28, 2026 | OKOYE, AFAMEFUNA | reporter.nih.gov |
| Mechanisms of Sensitization in High Risk Corneal Grafts | NIH | National Eye Institute | 2021 to 2025 | $3,336,083 | August 1, 2000 | July 31, 2027 | DANA, REZA | reporter.nih.gov |
| DNA-based Immune Phenotyping in HNSCC for Biomarkers of Response to Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $3,333,223 | January 1, 2021 | December 31, 2026 | KELSEY, KARL TIMOTHY | reporter.nih.gov |
| Clinically Translatable MRI Reporter Genes and Imaging Methods with Ultra-High Specificity and Sensitivity | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $3,332,874 | April 1, 2021 | December 31, 2028 | FARRAR, CHRISTIAN T | reporter.nih.gov |
| Role of Adaptive Immunity in Etiology of Alzheimer’s Disease andAlzheimer’s Disease-Related Dementias | NIH | National Institute on Aging | 2022 to 2025 | $3,330,838 | September 15, 2022 | May 31, 2027 | WALLACE, DOUGLAS C | reporter.nih.gov |
| Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,328,254 | April 1, 2022 | September 30, 2026 | LIM, WENDELL A | reporter.nih.gov |
| Toward development of senolytic CAR T cells | NIH | National Institute on Aging | 2025 | $3,326,400 | May 15, 2020 | August 31, 2029 | LOWE, SCOTT W. | reporter.nih.gov |
| Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,325,791 | April 1, 2022 | March 31, 2027 | KUHNS, MICHAEL S | reporter.nih.gov |
| Enhancing Treg Therapeutic Efficacy in GVHD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,322,892 | April 15, 2014 | March 31, 2027 | BLAZAR, BRUCE R | reporter.nih.gov |
| TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,322,837 | August 1, 2021 | July 31, 2026 | BOULWARE, DAVID R | reporter.nih.gov |
| Innate Immunity Stimulation Effects on Biomarkers, Cognition, and the Vascular Amyloid Proteome in a Squirrel Monkey Model of Sporadic CAA | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,321,272 | July 15, 2022 | June 30, 2027 | SCHOLTZOVA, HENRIETA | reporter.nih.gov |
| The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,320,824 | June 15, 2021 | March 31, 2027 | MUNSON, JENNIFER M | reporter.nih.gov |
| Career Development in Pediatric and Medical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,314,336 | September 30, 1997 | August 31, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| ARIA Pathophysiology Characterized by in vivo Neuroimaging, Plasma Biomarkers and Post-Mortem Proteomics | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $3,310,951 | June 4, 2025 | May 31, 2027 | WISNIEWSKI, THOMAS M | reporter.nih.gov |
| Multimodal PET-CT imaging of SIVmac239 dynamics post-ART interruption | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,302,677 | July 21, 2025 | June 30, 2029 | OKOYE, AFAMEFUNA | reporter.nih.gov |
| The B7x pathways in the tumor microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $3,299,614 | July 1, 2014 | November 30, 2026 | ZANG, XINGXING | reporter.nih.gov |
| Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas | NIH | National Cancer Institute | 2021 to 2025 | $3,294,656 | August 6, 2021 | July 31, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| FAST-FNA immune cell profiling in HNSCC | NIH | National Cancer Institute | 2021 to 2025 | $3,293,259 | January 26, 2021 | December 31, 2025 | WEISSLEDER, MD, PHD, RALPH | reporter.nih.gov |
| Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,291,872 | July 1, 2020 | June 30, 2025 | ANTHONY, ROBERT MCCULLOUGH | reporter.nih.gov |
| Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy | NIH | National Cancer Institute | 2021 to 2024 | $3,284,686 | September 1, 2019 | August 31, 2025 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Immune modulating therapies to treat complex regional pain syndrome | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,283,186 | September 30, 2022 | August 31, 2027 | AJIT, SEENA | reporter.nih.gov |
| IL-27R signaling as a negative regulator of innate and adaptive anti-cancer immunity in hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $3,273,154 | August 1, 2022 | July 31, 2027 | KOLTSOVA, EKATERINA | reporter.nih.gov |
| Determinants of differentiation and maintenance of PD-1+ CD8 T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,265,402 | June 1, 2021 | May 31, 2026 | KAMPHORST, ALICE OLIFFSON | reporter.nih.gov |
| Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,255,352 | September 16, 2020 | August 31, 2025 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,252,105 | April 1, 2022 | August 31, 2027 | POWELL, DANIEL J. | reporter.nih.gov |
| AAV-delivered HIV inhibitors for SHIV therapy | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,245,455 | August 15, 2022 | May 31, 2027 | GARDNER, MATTHEW RYAN | reporter.nih.gov |
| Evolution of T cell immunity in blood and tissues over childhood | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,243,813 | March 16, 2022 | February 28, 2027 | FARBER, DONNA L. | reporter.nih.gov |
| Using microfluidics to realize patient-specific anti-cancer immunotherapies | NIH | National Cancer Institute | 2023 to 2025 | $3,242,400 | September 19, 2023 | August 31, 2028 | FORDYCE, POLLY MORRELL | reporter.nih.gov |
| Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients | NIH | National Cancer Institute | 2021 to 2025 | $3,235,983 | July 1, 2020 | June 30, 2027 | LAROCCA, CECILIA | reporter.nih.gov |
| Genetic and Structural Basis for Virus Neutralization of Paramyxoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,230,785 | September 16, 2024 | September 15, 2027 | reporter.nih.gov | |
| Imaging Modulation of Immune Phenotype | NIH | National Cancer Institute | 2021 to 2025 | $3,227,270 | February 1, 2021 | January 31, 2027 | FERRARA, KATHERINE W | reporter.nih.gov |
| Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments | NIH | National Cancer Institute | 2021 to 2025 | $3,224,380 | March 17, 2021 | February 28, 2027 | KUO, CALVIN J | reporter.nih.gov |
| Targeting innate immunity for induction of robust renal allograft tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,224,166 | July 25, 2023 | April 30, 2028 | KAWAI, TATSUO | reporter.nih.gov |
| Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,224,130 | January 19, 2022 | December 31, 2026 | RUTISHAUSER, RACHEL LENA | reporter.nih.gov |
| Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,218,917 | August 15, 2015 | June 30, 2026 | JENQ, ROBERT | reporter.nih.gov |
| Characterization of Antigen-Specific Immune Response in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $3,213,011 | August 11, 2025 | July 31, 2029 | ELYAMAN, WASSIM | reporter.nih.gov |
| Outcomes for CLL patients treated with novel therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,205,518 | September 15, 2021 | August 31, 2026 | KAY, NEIL E | reporter.nih.gov |
| Therapeutic Targeting of RNA Splicing in Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,199,527 | February 5, 2018 | May 31, 2028 | WESTBROOK, THOMAS | reporter.nih.gov |
| Uncovering the metabolic underpinnings of T cell exhaustion | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,195,086 | September 19, 2022 | July 31, 2027 | DELGOFFE, GREG M. | reporter.nih.gov |
| Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,194,826 | January 1, 2025 | December 31, 2026 | SEGAL, LEOPOLDO NICOLAS | reporter.nih.gov |
| VISTA is a negative checkpoint regulator of innate immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,194,465 | May 6, 2020 | April 30, 2025 | SKOPELJA-GARDNER, SLADJANA | reporter.nih.gov |
| Immunomodulation in AAV gene therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,192,404 | August 21, 2025 | July 31, 2029 | ASOKAN, ARAVIND | reporter.nih.gov |
| Co-Clinical Research Resource for Imaging Tumor Associated Macrophages | NIH | National Cancer Institute | 2021 to 2025 | $3,191,659 | September 15, 2021 | August 31, 2026 | DALDRUP-LINK, HEIKE ELIZABETH | reporter.nih.gov |
| Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,185,429 | September 21, 2021 | August 31, 2026 | AFT, REBECCA L. | reporter.nih.gov |
| Natural killer cells subvert immune checkpoint therapy of tumors | NIH | National Cancer Institute | 2025 | $3,182,665 | September 24, 2025 | August 31, 2029 | YOKOYAMA, WAYNE M. | reporter.nih.gov |
| Developing preclinical xenograft models in zebrafish. | NIH | Office of the Director, National Institutes of Health | 2022 to 2025 | $3,178,512 | March 1, 2022 | February 28, 2026 | LANGENAU, DAVID MICHAEL | reporter.nih.gov |
| Regulatory T cells in cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,178,434 | July 1, 2021 | June 30, 2026 | ZOU, WEIPING | reporter.nih.gov |
| Drug eluting injectable biomaterials for next generation chemoembolization | NIH | National Cancer Institute | 2021 to 2025 | $3,173,416 | May 1, 2021 | April 30, 2027 | OKLU, RAHMI | reporter.nih.gov |
| Intrarenal B cells in acute kidney allograft rejection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,165,260 | February 15, 2020 | January 31, 2026 | CHONG, ANITA S | reporter.nih.gov |
| Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,159,973 | September 16, 2021 | August 31, 2026 | WU, JIA | reporter.nih.gov |
| Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,158,683 | July 21, 2016 | June 30, 2027 | CHEN, YI-GUANG | reporter.nih.gov |
| Spatial functional genomics to identify regulators of the tumor microenvironment and cancer immunity | NIH | National Cancer Institute | 2023 to 2025 | $3,154,814 | September 19, 2023 | August 31, 2028 | BROWN, BRIAN D | reporter.nih.gov |
| Immunotherapy via engineered therapeutic programs in tumors using RNA | NIH | National Cancer Institute | 2021 to 2025 | $3,154,064 | September 20, 2021 | August 31, 2027 | WEISS, RON | reporter.nih.gov |
| Regulation of immunity by the cGAS-STING pathway | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,152,902 | September 19, 2022 | July 31, 2027 | KAGAN, JONATHAN C | reporter.nih.gov |
| Targeting Pediatric Cancer Vulnerabilities | NIH | National Cancer Institute | 2023 to 2025 | $3,144,539 | September 19, 2023 | August 31, 2030 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| CD4+ T cells and neoantigens in melanoma immunotherapy. | NIH | National Cancer Institute | 2021 to 2025 | $3,143,740 | December 1, 2020 | November 30, 2026 | WANG, RONGFU | reporter.nih.gov |
| The role of semen in induction of paternal-specific tolerance during pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,142,758 | February 25, 2021 | January 31, 2027 | VOJTECH, LUCIA N | reporter.nih.gov |
| System Dynamics of PD-1 Signaling in T Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,142,181 | May 3, 2021 | April 30, 2027 | HLAVACEK, WILLIAM S | reporter.nih.gov |
| Allergen Loaded Nanoparticles for Food Allergy Tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,140,831 | September 16, 2020 | August 31, 2025 | SHEA, LONNIE D | reporter.nih.gov |
| Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,134,067 | June 1, 2019 | March 31, 2027 | WANG, HONGJUN | reporter.nih.gov |
| CONTROL AND ACTIVATION OF THE TUMOR NECROSIS FACTOR RECEPTORS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,130,533 | February 1, 2020 | June 30, 2025 | WAGNER, GERHARD | reporter.nih.gov |
| Optimizing anti-microbial immunity by targeting Sts-1 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,125,627 | July 23, 2025 | June 30, 2029 | CARPINO, NICHOLAS A | reporter.nih.gov |
| Innate lymphoid cell regulation of the host-microbiota interactions in cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,122,275 | September 20, 2022 | August 31, 2027 | SONNENBERG, GREGORY F | reporter.nih.gov |
| Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation. | NIH | National Cancer Institute | 2021 to 2025 | $3,119,515 | July 1, 2020 | June 30, 2027 | VINCENT, BENJAMIN G | reporter.nih.gov |
| Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,119,133 | January 1, 2021 | December 31, 2026 | YOON, HARRY H | reporter.nih.gov |
| Targeted immune therapies in heart transplantation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,118,293 | February 1, 2023 | January 31, 2026 | ABDI, REZA | reporter.nih.gov |
| Small molecule enhancers of tumor immunity targeting the LPA5 GPCR | NIH | National Cancer Institute | 2022 to 2025 | $3,114,085 | August 1, 2022 | July 31, 2026 | TIGYI, GABOR J | reporter.nih.gov |
| Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,113,004 | August 8, 2022 | July 31, 2027 | PHELPS, MITCH A | reporter.nih.gov |
| PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors) | NIH | National Cancer Institute | 2024 to 2025 | $3,108,431 | May 1, 2024 | April 30, 2026 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Evaluation of the Mechanisms Underlying Induction and Maintenance Immunosuppression Impact on T Cell Function after Kidney Transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,106,301 | July 16, 2025 | June 30, 2029 | SCHAENMAN, JOANNA M | reporter.nih.gov |
| VPS72 controls Treg cell stability and adaptation to tumor microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $3,103,834 | September 19, 2023 | August 31, 2028 | MI, QING-SHENG | reporter.nih.gov |
| Mechanisms of myocarditis and progressive cardiac fibrosis in chronic Trypanosoma cruzi infection. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,103,804 | March 18, 2022 | February 28, 2027 | JONES, KATHRYN MARIE | reporter.nih.gov |
| Engineering T cells to Promote Islet Transplant | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,102,316 | April 1, 2022 | March 31, 2027 | RILEY, JAMES L. | reporter.nih.gov |
| Engineered Immune Cells for T1D | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,097,818 | April 1, 2022 | March 31, 2026 | MEYER, EVERETT | reporter.nih.gov |
| Vascularized NICHE with local immunosuppression for cell replacement for Type 1 diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,096,729 | September 12, 2022 | May 31, 2027 | GRATTONI, ALESSANDRO | reporter.nih.gov |
| Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,092,811 | February 15, 2021 | January 31, 2026 | DONAHUE, TIMOTHY R | reporter.nih.gov |
| Immune determinants of progression from Oral Epithelial Dysplasia to Oral Squamous Cell Carcinoma by precision multiplexed imaging | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $3,081,662 | June 15, 2022 | March 31, 2027 | SPITZER, MATTHEW | reporter.nih.gov |
| Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,081,124 | January 16, 2020 | December 31, 2024 | YANG, OTTO O | reporter.nih.gov |
| Privileged and primitive hematopoietic stem cells, niches, and regulatory T cells | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,081,005 | December 1, 2021 | November 30, 2025 | FUJISAKI, JOJI | reporter.nih.gov |
| Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay | NIH | National Cancer Institute | 2022 to 2025 | $3,075,394 | September 1, 2022 | August 31, 2027 | WU, YUN | reporter.nih.gov |
| Precision targeting of T cell cytotoxicity with PET | NIH | National Cancer Institute | 2021 to 2025 | $3,067,538 | March 1, 2021 | February 28, 2026 | EVANS, MICHAEL JOHN | reporter.nih.gov |
| Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,062,772 | September 22, 2021 | August 31, 2026 | MUNN, LANCE L. | reporter.nih.gov |
| CD28-KITv CAR T cells with PD-1 dominant negative receptor | NIH | National Cancer Institute | 2024 to 2025 | $3,061,861 | March 1, 2024 | February 28, 2026 | ADUSUMILLI, PRASAD S. | reporter.nih.gov |
| Regulatory T Cells in Alzheimer's Disease | NIH | National Institute on Aging | 2022 to 2025 | $3,059,816 | August 16, 2022 | May 31, 2027 | FARRAR, MICHAEL ARCHIBALD | reporter.nih.gov |
| Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $3,056,754 | April 1, 2021 | March 31, 2027 | DAVIS, KARA LYNN | reporter.nih.gov |
| Beta-2 adrenergic signaling in immune homeostasis and reconstitution | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,048,780 | April 15, 2022 | March 31, 2027 | CAO, XUEFANG | reporter.nih.gov |
| Building the foundations of commensal vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,047,222 | September 23, 2022 | August 31, 2027 | FISCHBACH, MICHAEL ANDREW | reporter.nih.gov |
| Acute Antibody Mediated Kidney Allograft Rejection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,037,635 | September 17, 2021 | August 31, 2026 | FAIRCHILD, ROBERT L | reporter.nih.gov |
| Controllable solid tumor immunotherapy based on a wireless thermos-activator | NIH | National Cancer Institute | 2025 | $3,036,844 | August 11, 2025 | July 31, 2029 | WANG, YINGXIAO | reporter.nih.gov |
| GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,034,670 | June 5, 2018 | March 31, 2025 | NAKAAR, VALERIAN | reporter.nih.gov |
| Single Cell Methods for Bioeffector Discovery and Analysis | NIH | National Cancer Institute | 2021 to 2025 | $3,031,845 | December 18, 2018 | July 31, 2029 | BACHMANN, BRIAN O | reporter.nih.gov |
| Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,027,518 | March 17, 2020 | February 28, 2025 | KARAKOUSIS, PETROS C | reporter.nih.gov |
| Validation of a novel 3D culture platform for TNBC treatment selection | NIH | National Cancer Institute | 2022 to 2025 | $3,027,149 | September 20, 2022 | August 31, 2027 | YUN, KYUSON | reporter.nih.gov |
| Host Directed Orynotide for MDR Gram Negative Bacterial Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,025,760 | July 21, 2023 | June 30, 2028 | SCHAAL, JUSTIN BLAINE | reporter.nih.gov |
| Engineering a Human Microphysiological System for the Characterization of Islet-Immune Interactions | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,023,310 | August 1, 2019 | July 31, 2025 | STABLER, CHERIE L | reporter.nih.gov |
| Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $3,015,518 | September 21, 2017 | August 31, 2024 | WEISSMAN, IRVING L. | reporter.nih.gov |
| The novel role of beta3 integrin in regulating alloimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,014,928 | February 14, 2022 | January 31, 2027 | ABDI, REZA | reporter.nih.gov |
| Mechanisms of T Cell Quiescence and Exhaustion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,001,713 | March 1, 2019 | February 28, 2029 | SARKAR, SUROJIT | reporter.nih.gov |
| Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | May 24, 2021 | April 30, 2025 | COBURN, GLEN ANDREW | reporter.nih.gov |
| Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,000,000 | April 17, 2020 | July 31, 2025 | JUNGHANS, RICHARD P | reporter.nih.gov |
| Therapy and Prophylaxis for Genital Tract Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,000,000 | February 1, 2013 | July 31, 2026 | AUCI, DOMINICK | reporter.nih.gov |
| Cancer Immunotherapy Trials Network Central Operations and Statistical Center | NIH | National Cancer Institute | 2021 to 2022 | $2,997,769 | September 22, 2010 | August 31, 2023 | DAVIDSON, NANCY ELLEN | reporter.nih.gov |
| Improving the translational value of head and neck cancer patient-in-mouse models | NIH | National Cancer Institute | 2021 to 2025 | $2,996,815 | July 1, 2021 | June 30, 2026 | KIMPLE, RANDALL J. | reporter.nih.gov |
| Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,996,021 | June 1, 2011 | January 31, 2027 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,995,034 | July 14, 2022 | June 30, 2026 | MARATHI, UPENDRA | reporter.nih.gov |
| (PQ6) Mesenchymal stem cell based and immunocompetent mouse models of HIV/AIDS KSHV-driven sarcomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,993,160 | April 8, 2021 | March 31, 2027 | SHEMBADE, NOULA DATTU | reporter.nih.gov |
| Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD) | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $2,992,236 | June 7, 2024 | May 31, 2026 | STEWART, CHARLES ANDREW | reporter.nih.gov |
| Mechanisms of Immune Activation in Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,991,557 | February 1, 2018 | December 31, 2025 | HARRISON, DAVID G | reporter.nih.gov |
| Regulation of PDAC metabolism and immunity by collagen and its cleavage products | NIH | National Cancer Institute | 2022 to 2025 | $2,987,434 | September 21, 2022 | August 31, 2025 | KARIN, MICHAEL | reporter.nih.gov |
| Humanized monoclonal antibodies to treat mucormycosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,987,094 | August 9, 2018 | February 28, 2027 | LAZAR, GARY | reporter.nih.gov |
| Comprehensive Liquid Biomarkers to Personalize Therapy in Renal Cell Carcinoma | NIH | National Cancer Institute | 2025 | $2,984,495 | September 23, 2025 | August 31, 2029 | MCKAY, RANA RAMZI | reporter.nih.gov |
| Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,984,199 | March 1, 2021 | February 28, 2026 | RADU, CAIUS GABRIEL | reporter.nih.gov |
| Genetically-engineered stem cells for self-regulating arthritis therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,983,611 | April 1, 2022 | March 31, 2027 | GUILAK, FARSHID | reporter.nih.gov |
| A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients | NIH | National Cancer Institute | 2021 to 2025 | $2,980,235 | April 1, 2021 | March 31, 2027 | KASEB, AHMED | reporter.nih.gov |
| Antigenic determinants of asthma-associated allergens for design of immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,974,640 | August 25, 2009 | August 31, 2030 | POMES, ANNA | reporter.nih.gov |
| Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,974,380 | May 1, 2022 | April 30, 2027 | SISE, MEGHAN E. | reporter.nih.gov |
| Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,974,321 | May 15, 2021 | February 28, 2027 | GOUTMAN, STEPHEN | reporter.nih.gov |
| Safety and Tolerability Studies for an Anti-Fibrin P2 Monoclonal Antibody for the Treatment of Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2023 | $2,970,786 | September 30, 2021 | August 31, 2024 | KANTOR, AARON B | reporter.nih.gov |
| Prevention and Treatment of Pneumocystis Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,969,486 | May 21, 2020 | April 30, 2026 | NORRIS, KAREN A | reporter.nih.gov |
| Microglia antigen presentation in the CNS of Alzheimer's disease | NIH | National Institute on Aging | 2021 to 2024 | $2,968,640 | May 15, 2020 | January 31, 2026 | ELYAMAN, WASSIM | reporter.nih.gov |
| Learning from the Ebola success: Can a mAb also save lives after yellow fever infection? | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,966,587 | August 6, 2021 | July 31, 2025 | WATKINS, DAVID I | reporter.nih.gov |
| Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,963,965 | February 1, 2021 | January 31, 2027 | CARBONE, DAVID P. | reporter.nih.gov |
| Innovative Tools for Chemical Synthesis: Metal-Hydride Catalysis, Medicinal Motifs, and Molecular Probes | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,959,295 | May 1, 2018 | July 31, 2028 | DONG, VY M | reporter.nih.gov |
| PD-1/PD-L1 modulation in cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,958,687 | June 21, 2010 | February 28, 2027 | PARDOLL, DREW M. | reporter.nih.gov |
| Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,957,885 | September 19, 2022 | August 31, 2027 | LARREGINA, ADRIANA T | reporter.nih.gov |
| SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local Immunotherapy | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,957,648 | July 1, 2021 | April 30, 2027 | YOUNG, SIMON | reporter.nih.gov |
| Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response | NIH | National Cancer Institute | 2021 to 2025 | $2,957,123 | June 1, 2021 | May 31, 2026 | BYERS, LAUREN AVERETT | reporter.nih.gov |
| Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response | NIH | National Cancer Institute | 2021 to 2025 | $2,952,871 | August 2, 2021 | July 31, 2027 | CURTI, BRENDAN D | reporter.nih.gov |
| Identifying and preventing antigen specific T cells in diabetes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,951,339 | June 22, 2021 | May 31, 2027 | FIFE, BRIAN T | reporter.nih.gov |
| A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,949,803 | August 8, 2017 | February 28, 2026 | MURAD, JOANA M | reporter.nih.gov |
| INSPIRE: Innovative Strategies for Personalized Immunotherapies and Reservoir Eradication | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,948,452 | July 24, 2025 | May 31, 2030 | JONES, R. BRAD | reporter.nih.gov |
| Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,945,301 | August 1, 2021 | June 30, 2027 | LI, SHULIN | reporter.nih.gov |
| Developing a Multi-epitope Pan-Coronavirus Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,944,787 | August 7, 2020 | July 31, 2025 | BENMOHAMED, LBACHIR | reporter.nih.gov |
| Multiomics characterization, induction, and elimination of the HIV gut reservoir | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,937,487 | July 15, 2022 | April 30, 2027 | ROAN, NADIA R | reporter.nih.gov |
| Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,937,308 | April 1, 2021 | March 31, 2026 | GENOVESE, GIANNICOLA | reporter.nih.gov |
| Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,937,157 | May 15, 2022 | April 30, 2027 | WONG, WILSON | reporter.nih.gov |
| Radiogenomic Credentialing of Head and Neck Cancer Models | NIH | National Cancer Institute | 2021 to 2025 | $2,932,365 | December 1, 2020 | November 30, 2026 | SESHADRI, MUKUND | reporter.nih.gov |
| Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $2,929,456 | August 1, 2020 | April 30, 2026 | BROWN, CHRISTINE | reporter.nih.gov |
| Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,924,883 | March 1, 2022 | February 28, 2027 | DERENZO, CHRISTOPHER | reporter.nih.gov |
| Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence | NIH | National Institute of Mental Health | 2023 to 2025 | $2,924,235 | June 1, 2023 | May 31, 2027 | TRAUTMANN, LYDIE | reporter.nih.gov |
| Diagnosing and predicting risk in children with SARS-CoV-2- related illness | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $2,924,117 | January 1, 2021 | November 30, 2024 | BURNS, JANE C | reporter.nih.gov |
| Immunomodulation of juvenile femoral head osteonecrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,923,511 | July 1, 2021 | March 31, 2027 | KIM, HARRY K.W. | reporter.nih.gov |
| A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,922,693 | February 23, 2021 | January 31, 2025 | FANGER, GARY | reporter.nih.gov |
| Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,921,132 | February 4, 2022 | April 30, 2025 | VALLADARES, RICARDO | reporter.nih.gov |
| Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,920,314 | August 1, 2016 | August 31, 2027 | DUNCAN, JAMES S | reporter.nih.gov |
| Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | NIH | National Cancer Institute | 2022 to 2025 | $2,917,317 | December 9, 2021 | November 30, 2026 | KENDERIAN, SAAD J. | reporter.nih.gov |
| Innate Immune Mechanisms Contributing to Cancer Growth in Obesity | NIH | National Cancer Institute | 2021 to 2025 | $2,914,829 | July 1, 2021 | June 30, 2026 | ENGLEMAN, EDGAR G. | reporter.nih.gov |
| Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $2,912,373 | September 1, 2021 | August 31, 2027 | LI, ZIHAI | reporter.nih.gov |
| A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,911,659 | January 20, 2018 | July 31, 2026 | YANG, ZHIYONG | reporter.nih.gov |
| Molecular Imaging and Theranostics of Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,907,093 | September 4, 2017 | March 31, 2025 | BHUJWALLA, ZAVER M. | reporter.nih.gov |
| iSTAR Tregs | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,906,574 | July 1, 2023 | June 30, 2027 | TANG, QIZHI | reporter.nih.gov |
| Dual-targeted DOTA CAR T cells with image-guided monitoring for solid tumor treatment | NIH | National Cancer Institute | 2024 to 2025 | $2,906,182 | September 9, 2024 | August 31, 2026 | POWELL, DANIEL J. | reporter.nih.gov |
| Non-invasive imaging of the anti-tumor immune response | NIH | National Cancer Institute | 2021 to 2025 | $2,904,564 | December 14, 2020 | November 30, 2026 | PISHESHA, NOVALIA | reporter.nih.gov |
| New Engineering Strategy for Harnessing Immune System against Head and Neck Cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,903,162 | July 1, 2021 | April 30, 2026 | MOON, JAMES J. | reporter.nih.gov |
| Personalized Adoptive T-cell Therapy for AML | NIH | National Cancer Institute | 2021 to 2025 | $2,900,444 | July 1, 2021 | December 31, 2026 | AVIGAN, DAVID E. | reporter.nih.gov |
| Targeted interventions to reduce or eliminate the SIV reservoir in a novel model of elite control | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,899,482 | April 16, 2020 | March 31, 2027 | HOXIE, JAMES A | reporter.nih.gov |
| Depleting autoantibodies for the treatment of autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,898,618 | March 11, 2022 | February 28, 2027 | KANNANGANAT SIDHARTHAN, SUNIL | reporter.nih.gov |
| Understanding and targeting epigentic regulation of immune evasion in prostate cancer | NIH | National Cancer Institute | 2025 | $2,895,540 | August 1, 2025 | July 31, 2029 | CAI, LING | reporter.nih.gov |
| Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles | NIH | National Cancer Institute | 2022 to 2025 | $2,889,170 | September 1, 2022 | August 31, 2027 | SAYOUR, ELIAS | reporter.nih.gov |
| Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,885,730 | July 1, 2022 | June 30, 2027 | BERGER, MICHAEL F. | reporter.nih.gov |
| Mechanoregulation of cytotoxic lymphocyte function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,881,658 | February 15, 2010 | June 30, 2026 | HUSE, MORGAN A | reporter.nih.gov |
| Natural Killer cells and the Immunogenetics of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,878,562 | September 1, 2021 | August 31, 2025 | NORMAN, PAUL JOHN | reporter.nih.gov |
| The role of cytotoxic T cells in rheumatoid arthritis pathogenesis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,877,343 | September 1, 2021 | August 31, 2026 | ANDRADE, FELIPE | reporter.nih.gov |
| An integrative structural biology approach to understanding metabolite recognition by cellular receptors | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,877,333 | September 1, 2017 | August 31, 2029 | SGOURAKIS, NIKOLAOS | reporter.nih.gov |
| Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,875,756 | June 1, 2020 | May 31, 2026 | ZHU, CHENG | reporter.nih.gov |
| Synthetic circuits that drive infiltration of therapeutic T cells into immunologically cold tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,872,622 | September 10, 2021 | August 31, 2026 | LIM, WENDELL A | reporter.nih.gov |
| Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies | NIH | National Cancer Institute | 2022 to 2025 | $2,872,577 | July 7, 2022 | September 2, 2025 | WANG, JIN | reporter.nih.gov |
| Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,867,908 | June 1, 2020 | May 31, 2026 | WALLER, EDMUND K | reporter.nih.gov |
| Understanding and Harnessing Microbial Reprogramming to Combat Carcinogenic Colibactin in Colorectal Cancer | NIH | National Cancer Institute | 2025 | $2,864,671 | September 10, 2025 | August 31, 2029 | LI, JIAHE | reporter.nih.gov |
| Mechanisms of CD4 T cell help to myeloid cells in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,863,501 | August 1, 2025 | July 31, 2029 | BOLD, TYLER DALLAS | reporter.nih.gov |
| The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,863,227 | April 14, 2021 | February 28, 2026 | LE, QUYNH-THU XUAN | reporter.nih.gov |
| Overcoming hypoxic resistance to anti-cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,861,132 | December 15, 2020 | May 31, 2026 | DENKO, NICHOLAS C. | reporter.nih.gov |
| A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies | NIH | National Cancer Institute | 2021 to 2025 | $2,860,221 | September 15, 2021 | August 31, 2026 | KINAHAN, PAUL E. | reporter.nih.gov |
| Determinants of T Cell Fate in Transplantation Tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,859,856 | August 1, 2022 | July 31, 2027 | FORD, MANDY L | reporter.nih.gov |
| Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment Following Hematopoietic Stem Cell Transplantation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,855,157 | May 1, 2020 | April 30, 2026 | KELLER, MICHAEL DANIEL | reporter.nih.gov |
| Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric | NIH | National Cancer Institute | 2022 to 2025 | $2,853,545 | February 11, 2022 | June 30, 2027 | DALDRUP-LINK, HEIKE ELIZABETH | reporter.nih.gov |
| Depleting exosomes to improve responses to immune therapy in HNSCC | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $2,851,264 | July 1, 2020 | June 30, 2025 | WHITESIDE, THERESA L. | reporter.nih.gov |
| Development of a platform for spatial functional genomics | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $2,847,613 | September 1, 2020 | June 30, 2025 | BROWN, BRIAN D | reporter.nih.gov |
| Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,841,134 | July 1, 2022 | June 30, 2027 | CHOUEIRI, TONI | reporter.nih.gov |
| Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,835,203 | May 1, 2022 | April 30, 2027 | YARCHOAN, MARK | reporter.nih.gov |
| Interrogating unique DC adaptations to tissue to promote barrier immunity and tolerance | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,834,511 | March 1, 2022 | January 31, 2027 | ANANDASABAPATHY, NIROSHANA | reporter.nih.gov |
| Engineer Immune Cells via Chemoenzymatic Glycan Editing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,832,957 | March 1, 2019 | February 28, 2025 | WU, PENG | reporter.nih.gov |
| Metabolic Regulation by SAPS3 of Virus-specific T cell Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,832,747 | July 14, 2025 | June 30, 2029 | TINOCO, ROBERTO | reporter.nih.gov |
| Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity | NIH | National Cancer Institute | 2022 to 2025 | $2,828,375 | September 1, 2022 | August 31, 2027 | BALACHANDRAN, VINOD P | reporter.nih.gov |
| Cell Directed Immunomodulation Therapy as a Bridge to Left Ventricular Device Implantation in Chronic Heart Failure Patients | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,827,948 | June 1, 2024 | May 31, 2027 | JOHNSTON, KIMBERLY ANNE | reporter.nih.gov |
| Polyamines and Hypusine in Type 1 Diabetes Pathogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,825,507 | May 7, 2020 | July 31, 2030 | MIRMIRA, RAGHAVENDRA G | reporter.nih.gov |
| Harnessing the nervous system to overcome resistance to immunotherapy in oral cancer | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $2,825,170 | August 1, 2022 | May 31, 2027 | AMIT, MORAN | reporter.nih.gov |
| Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,822,799 | May 1, 2020 | October 31, 2026 | PETERS, ULRIKE | reporter.nih.gov |
| NANOPHOTOSENSITIZERS FOR REGENERATIVE PHOTOTHERAPY | NIH | National Cancer Institute | 2022 to 2025 | $2,822,017 | August 4, 2021 | July 31, 2027 | ACHILEFU, SAMUEL | reporter.nih.gov |
| Control of Regulatory T Cell Function by Toll-Like Receptor 7 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,821,715 | July 1, 2021 | June 30, 2026 | BARTON, GREGORY M | reporter.nih.gov |
| Systems-level identification of key regulators deciding immune cell state | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,820,642 | April 1, 2020 | March 31, 2026 | WANG, WEI | reporter.nih.gov |
| Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,819,549 | May 12, 2023 | April 30, 2027 | AMAN, M JAVAD | reporter.nih.gov |
| Advancing Cancer Therapy through Groundbreaking Research in Radiation Biology | NIH | National Cancer Institute | 2021 to 2022 | $2,817,393 | January 4, 2016 | April 30, 2023 | KIRSCH, DAVID GUY | reporter.nih.gov |
| DAP12 and the host response to cryptococcosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,814,936 | July 12, 2021 | June 30, 2026 | HEUNG, LENA J | reporter.nih.gov |
| The role of the intestinal microbiome in cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,811,009 | August 1, 2023 | July 31, 2030 | VAN DEN BRINK, MARCEL R M | reporter.nih.gov |
| Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,809,344 | August 1, 2021 | July 31, 2026 | LITTMAN, DAN | reporter.nih.gov |
| Inflammation-driven T Cell Responses and their Dichotomous Effect on Host Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,806,788 | December 1, 2016 | July 31, 2027 | PRLIC, MARTIN | reporter.nih.gov |
| Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,795,412 | January 20, 2022 | December 31, 2026 | STETSON, DANIEL B | reporter.nih.gov |
| Re-wiring PDAC Tumor Immunity Through Dendritic Cells | NIH | National Cancer Institute | 2021 to 2025 | $2,793,464 | September 22, 2021 | August 31, 2026 | DENARDO, DAVID G | reporter.nih.gov |
| Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $2,786,444 | August 1, 2018 | July 31, 2024 | PARK, JULIE R | reporter.nih.gov |
| A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,785,861 | September 1, 2022 | June 30, 2027 | RODRIGUEZ-RODRIGUEZ, LORNA | reporter.nih.gov |
| Mechanisms of regulatory T cell-mediated recovery from severe viral pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,783,450 | March 1, 2020 | June 30, 2029 | SINGER, BENJAMIN DAVID | reporter.nih.gov |
| Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment | NIH | National Cancer Institute | 2022 to 2025 | $2,781,650 | September 1, 2022 | August 31, 2027 | PASCA DI MAGLIANO, MARINA | reporter.nih.gov |
| Next Generation GPC2-CARs for Medulloblastoma | NIH | National Cancer Institute | 2024 to 2025 | $2,781,440 | September 13, 2024 | August 31, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| Vascularized Islet transplantation NICHE with local immunosuppression for the treatment of type 1 diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,778,087 | July 1, 2022 | April 30, 2027 | GRATTONI, ALESSANDRO | reporter.nih.gov |
| Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial | NIH | National Cancer Institute | 2021 to 2025 | $2,776,685 | July 21, 2015 | June 30, 2026 | JAFFEE, ELIZABETH M. | reporter.nih.gov |
| Treating colon cancer by regulating intestinal immunity through microbial metabolism | NIH | National Cancer Institute | 2021 to 2025 | $2,772,249 | June 1, 2021 | May 31, 2027 | ARPAIA, NICHOLAS | reporter.nih.gov |
| A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity | NIH | National Cancer Institute | 2022 to 2025 | $2,770,577 | February 24, 2022 | January 31, 2027 | DIEFENBACH, CATHERINE SIBYL | reporter.nih.gov |
| Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | NIH | National Cancer Institute | 2022 to 2025 | $2,766,745 | July 1, 2022 | June 30, 2027 | JIM, HEATHER S.L. | reporter.nih.gov |
| Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,766,158 | September 1, 2023 | August 31, 2028 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| A deubiquitination module controls Treg adaptation to tumor microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $2,761,442 | January 1, 2021 | December 31, 2026 | FANG, DEYU | reporter.nih.gov |
| Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface | NIH | National Cancer Institute | 2021 to 2025 | $2,759,610 | August 1, 2021 | July 31, 2027 | SWARTZ, MELODY ANN | reporter.nih.gov |
| Supramolecular biomaterials for tuning the inflammatory properties of the complement system | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,759,425 | June 1, 2022 | May 31, 2027 | COLLIER, JOEL H | reporter.nih.gov |
| Regulation of anti-tumor immunity by HDAC11 | NIH | National Cancer Institute | 2021 to 2024 | $2,757,378 | June 1, 2020 | May 31, 2026 | SETO, EDWARD | reporter.nih.gov |
| Understanding the functional agility of effector memory CD8 T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,757,180 | July 9, 2021 | June 30, 2027 | HAMILTON HART, SARA ELIZABETH | reporter.nih.gov |
| Lactate production by tumor associated macrophages promotes tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,756,946 | March 1, 2021 | February 28, 2026 | BECKER, LEV | reporter.nih.gov |
| CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,756,416 | August 9, 2023 | July 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Therapeutic targeting MDSC-mediated immune suppression in cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,755,158 | December 13, 2021 | November 30, 2026 | NEFEDOVA, YULIA | reporter.nih.gov |
| Bispecific immunotherapeutic delivery system for lung diseases | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,754,456 | August 1, 2023 | May 31, 2027 | SCHNITZER, JAN EUGENIUSZ | reporter.nih.gov |
| Nuclear Receptor Control of T Cell Function in Discrete Intestinal Microenvironments | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,751,010 | September 23, 2021 | August 31, 2026 | SUNDRUD, MARK SCOTT | reporter.nih.gov |
| Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,750,290 | April 1, 2020 | March 31, 2025 | BHARDWAJ, NINA | reporter.nih.gov |
| [18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,748,177 | January 21, 2022 | December 31, 2026 | SEO, YOUNGHO | reporter.nih.gov |
| Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,744,402 | April 1, 2022 | December 31, 2025 | KESELOWSKY, BENJAMIN GEORGE | reporter.nih.gov |
| In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,743,808 | January 10, 2023 | December 31, 2027 | LIEBER, ANDRE MICHAEL | reporter.nih.gov |
| Credentialing Models of Invasive Lobular Breast Cancer for Translational Research | NIH | National Cancer Institute | 2021 to 2025 | $2,743,261 | April 1, 2021 | March 31, 2027 | OESTERREICH, STEFFI | reporter.nih.gov |
| Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors | NIH | National Cancer Institute | 2023 to 2025 | $2,739,146 | August 1, 2023 | July 31, 2030 | MILLER, JEFFREY S. | reporter.nih.gov |
| Development and characterization of engineered therapeutic antibodies against SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,738,360 | August 1, 2021 | July 31, 2024 | AMARASINGHE, GAYA K. | reporter.nih.gov |
| Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,735,518 | September 22, 2022 | August 31, 2027 | GRUBER, STEPHEN B | reporter.nih.gov |
| In Vivo Gene Editing of B cells with NICE-AAV Vectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,735,041 | December 16, 2021 | November 30, 2026 | PETERSON, CHRISTOPHER W | reporter.nih.gov |
| Hexokinase 2 and cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,734,879 | July 1, 2021 | June 30, 2027 | HAY, NISSIM | reporter.nih.gov |
| Systemic RNA Delivery to Tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,731,905 | December 21, 2015 | June 30, 2027 | SHI, JINJUN | reporter.nih.gov |
| The role of IL-27 in sustaining the exhausted CD8 T cell response to persistent infection and cancer. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,729,120 | July 6, 2021 | June 30, 2027 | TEIJARO, JOHN ROSS | reporter.nih.gov |
| Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel | NIH | National Cancer Institute | 2021 to 2024 | $2,726,050 | September 1, 2020 | May 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma | NIH | National Cancer Institute | 2023 to 2025 | $2,724,833 | August 1, 2023 | July 31, 2028 | OLSON, JAMES M | reporter.nih.gov |
| Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome | NIH | National Cancer Institute | 2022 to 2025 | $2,721,586 | August 22, 2022 | July 31, 2027 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| Identifying therapeutic pathways targeting medulloblastoma-immune cell interactions | NIH | National Cancer Institute | 2021 to 2025 | $2,721,281 | May 1, 2021 | April 30, 2027 | FRAENKEL, ERNEST | reporter.nih.gov |
| Enhancing Innate and Adaptive Immunity to Improve Sepsis Survival | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,718,598 | May 1, 2018 | April 30, 2028 | HOTCHKISS, RICHARD SAMUEL | reporter.nih.gov |
| Implications of Changes in Islet Exosomal Cargo in Type 1 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,718,093 | September 19, 2022 | July 31, 2027 | SIMS, EMILY K | reporter.nih.gov |
| HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,717,589 | September 19, 2023 | August 31, 2025 | YEE, CASSIAN | reporter.nih.gov |
| Next generation T cell therapies for mutant KRAS solid tumors | NIH | National Cancer Institute | 2023 to 2024 | $2,717,473 | September 1, 2023 | August 31, 2025 | CARRENO, BEATRIZ M. | reporter.nih.gov |
| Combination host-directed and antibacterial therapy for pulmonary intracellular infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,715,913 | November 13, 2017 | June 30, 2029 | STAYTON, PATRICK S. | reporter.nih.gov |
| Determinants of response to cancer immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $2,714,641 | August 1, 2021 | July 31, 2024 | FONG, LAWRENCE | reporter.nih.gov |
| [18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events | NIH | National Cancer Institute | 2022 to 2025 | $2,714,023 | September 1, 2022 | August 31, 2027 | PIWNICA-WORMS, DAVID | reporter.nih.gov |
| Development of a B Cell Therapeutic | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,713,112 | August 20, 2020 | July 31, 2025 | DITTEL, BONNIE N | reporter.nih.gov |
| Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,712,785 | May 11, 2021 | April 30, 2026 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization | NIH | National Cancer Institute | 2021 to 2025 | $2,704,913 | September 16, 2021 | June 30, 2027 | HEATH, JAMES R. | reporter.nih.gov |
| Regulation of T cell exhaustion via 3D chromatin architecture | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,704,065 | March 15, 2015 | April 30, 2030 | XUE, HAI-HUI | reporter.nih.gov |
| Gamma delta T cell based melanoma therapies | NIH | National Cancer Institute | 2022 to 2025 | $2,700,439 | December 13, 2021 | November 30, 2026 | XU, XIAOWEI | reporter.nih.gov |
| Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122 | NIH | National Cancer Institute | 2022 to 2025 | $2,699,777 | February 15, 2022 | December 31, 2026 | HAFLER, DAVID A. | reporter.nih.gov |
| Pathobiology of ANCA Glomerulonephritis: Targeting Adaptive and Innate Immune Processes for Precision Therapies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,693,358 | July 1, 2020 | May 31, 2025 | FALK, RONALD J | reporter.nih.gov |
| Soluble mediators of relapse | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,692,344 | May 1, 2021 | April 30, 2026 | CHUGH, SUMANT SINGH | reporter.nih.gov |
| Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction | NIH | National Cancer Institute | 2021 to 2025 | $2,692,281 | July 6, 2021 | June 30, 2026 | MORAN, AMY E | reporter.nih.gov |
| Targeted cell-depleting immunotherapy for TB and HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,691,184 | February 25, 2020 | January 31, 2026 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Spatially resolved, single cell biomarkers of B cell lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,690,152 | August 1, 2022 | July 31, 2027 | MERCHANT, AKIL | reporter.nih.gov |
| A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies | NIH | National Cancer Institute | 2022 to 2025 | $2,688,808 | March 1, 2022 | February 28, 2027 | REINHERZ, ELLIS L | reporter.nih.gov |
| Deciphering the molecular control of intratumoral dendritic cells | NIH | National Cancer Institute | 2021 to 2025 | $2,688,550 | February 1, 2021 | January 31, 2026 | MERAD, MIRIAM | reporter.nih.gov |
| ART Modulation of Viral Pathogenesis | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,687,436 | May 15, 2007 | August 11, 2029 | DITTMER, DIRK P | reporter.nih.gov |
| The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,686,770 | August 1, 2021 | July 31, 2026 | NEWELL, EVAN | reporter.nih.gov |
| Resistance to T cell exhaustion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,684,995 | September 22, 2021 | August 31, 2027 | ZAJAC, ALLAN J | reporter.nih.gov |
| A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,684,733 | August 1, 2024 | May 31, 2027 | GILKESON, GARY S | reporter.nih.gov |
| B-lymphocyte Targeting Therapies for Autoimmune Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,678,494 | April 1, 2013 | March 31, 2026 | SERREZE, DAVID V | reporter.nih.gov |
| New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,677,568 | February 1, 2022 | December 31, 2026 | SCHNEEWEISS, SEBASTIAN G. | reporter.nih.gov |
| Gut symbiotic microbiota-derived CD1d ligands and their immunomodulatory mechanisms | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,675,501 | June 14, 2022 | May 31, 2027 | OH, SUNGWHAN F | reporter.nih.gov |
| Cancer Resistant Mice | NIH | National Cancer Institute | 2022 to 2025 | $2,674,668 | December 1, 2021 | November 30, 2026 | BEUTLER, BRUCE A | reporter.nih.gov |
| Selective disruption of histone deacetylase complexes using protein interaction modulators | NIH | National Cancer Institute | 2022 to 2025 | $2,674,355 | February 1, 2022 | January 31, 2027 | VIDAL, MARC | reporter.nih.gov |
| Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases | NIH | National Cancer Institute | 2021 to 2024 | $2,674,209 | December 15, 2019 | November 30, 2025 | GERSTNER, ELIZABETH | reporter.nih.gov |
| Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,673,041 | August 2, 2022 | July 31, 2027 | NEAMATI, NOURI | reporter.nih.gov |
| Imaging Acidosis and Immune Therapy in PDAC | NIH | National Cancer Institute | 2021 to 2024 | $2,672,496 | February 1, 2020 | January 31, 2026 | PILON-THOMAS, SHARI | reporter.nih.gov |
| Th9 cells and protective TB immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,670,376 | March 9, 2022 | February 28, 2027 | HOFT, DANIEL F. | reporter.nih.gov |
| The role of the innate immune cell cyclooxygenase/prostaglandin system in blood pressureregulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,667,442 | December 20, 2002 | June 30, 2028 | HARRIS, RAYMOND C. | reporter.nih.gov |
| Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,663,582 | February 15, 2021 | January 31, 2026 | BLAZAR, BRUCE R | reporter.nih.gov |
| BAFF-R CAR T cell therapy for ALL | NIH | National Cancer Institute | 2022 to 2025 | $2,663,058 | April 18, 2022 | March 31, 2027 | WANG, XIULI | reporter.nih.gov |
| A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,662,971 | April 1, 2022 | March 31, 2027 | FANGER, NEIL A | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston, MA | 148 | $233.1 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 176 | $214.1 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 145 | $208.6 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 102 | $199.8 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 136 | $192.6 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 96 | $189.8 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 152 | $184.8 million | 0 | $0 |
| Washington University | Saint Louis, MO | 141 | $174.4 million | 0 | $0 |
| Stanford University | Stanford, CA | 163 | $171.8 million | 0 | $0 |
| Emory University | Atlanta, GA | 115 | $168.2 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 150 | $153.1 million | 0 | $0 |
| Duke University | Durham, NC | 91 | $129.2 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 108 | $127.6 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 75 | $117.2 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 86 | $109.2 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 110 | $108.2 million | 0 | $0 |
| Yale University | New Haven, CT | 92 | $105.9 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 92 | $105.6 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 96 | $102.8 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 69 | $100.4 million | 0 | $0 |
| Ohio State University | Columbus, OH | 81 | $95.5 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 85 | $94.1 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 75 | $90.8 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 25 | $89.8 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 72 | $87 million | 0 | $0 |
| University of Florida | Gainesville, FL | 75 | $84.6 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 81 | $84.1 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 81 | $80.3 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 47 | $79.5 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 41 | $77.3 million | 0 | $0 |
| University of Chicago | Chicago, IL | 63 | $76.3 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 56 | $73.9 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 29 | $72.3 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 45 | $72.3 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 24 | $70.4 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 40 | $70 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 61 | $69.8 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 46 | $69.6 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 58 | $69.2 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 64 | $66.9 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 47 | $65 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 44 | $62.7 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 31 | $59.9 million | 0 | $0 |
| University of Washington | Seattle, WA | 46 | $59.5 million | 0 | $0 |
| Roswell Park Cancer Institute Corp | Buffalo, NY | 52 | $58.9 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 28 | $55.6 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 52 | $54.3 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 37 | $52.9 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 52 | $51.7 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 30 | $49.2 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 23 | $48.7 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 40 | $47.9 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 35 | $43.7 million | 0 | $0 |
| Augusta University | Augusta, GA | 26 | $39.1 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 37 | $37.5 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 35 | $37.3 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 28 | $35.6 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 29 | $35.5 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 31 | $34.5 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 26 | $34.4 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 39 | $33.5 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 33 | $33.4 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 31 | $31.8 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 25 | $30.7 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 31 | $29.4 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 29 | $29.1 million | 0 | $0 |
| University of California at Davis | Davis, CA | 31 | $28.8 million | 0 | $0 |
| Rockefeller University | New York, NY | 16 | $27.6 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 15 | $26.7 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 7 | $25.9 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 23 | $25.6 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 17 | $24.4 million | 0 | $0 |
| Institute for Molecular Medicine | Huntington Beach, CA | 3 | $23.9 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 19 | $23.1 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 22 | $23.1 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 21 | $22.7 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 15 | $22.7 million | 0 | $0 |
| University of Louisville | Louisville, KY | 18 | $21.9 million | 0 | $0 |
| California Institute of Technology | Pasadena, CA | 6 | $20.4 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 19 | $20.3 million | 0 | $0 |
| George Washington University | Washington, DC | 20 | $19.9 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 10 | $19.9 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 14 | $19.5 million | 0 | $0 |
| University of Rochester | Rochester, NY | 19 | $19.3 million | 0 | $0 |
| Intervexion Therapeutics, LLC | Little Rock, AR | 2 | $19.1 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 31 | $18.7 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 17 | $18.6 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 15 | $18.2 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 20 | $17.6 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 16 | $17.1 million | 0 | $0 |
| Brown University | Providence, RI | 9 | $17 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 20 | $16.6 million | 0 | $0 |
| Benaroya Research Inst at Virginia Mason | Seattle, WA | 10 | $16.1 million | 0 | $0 |
| Salk Institute for Biological Studies | La Jolla, CA | 15 | $16 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 17 | $15.5 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 15 | $15.5 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 32 | $15.4 million | 0 | $0 |
| Institute for Systems Biology | Seattle, WA | 4 | $15.3 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 18 | $15.2 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 9 | $15.2 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 3,120 | $1,818,469,862 | 0 | $0 |
| 2024 | 3,141 | $1,606,355,370 | 0 | $0 |
| 2023 | 3,077 | $1,578,692,584 | 0 | $0 |
| 2022 | 2,914 | $1,438,657,016 | 0 | $0 |
| 2021 | 2,746 | $1,377,972,538 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 56 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 15 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 11 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 6 awards here | |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | September 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required) | PA-24-181 | NIH | May 8, 2027 | Not listed | Notice number printed on 1 award here | |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) | PA-25-304 | NIH | January 7, 2028 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 1,386 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,386 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.